This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

The U.S. FDA-approved Aprepitant for the treatment of chronic myeloid leukemia (CML) on October 29, 2007. 

Mechanism of Action of undefined

BCR-ABL tyrosine kinase is responsible for the uncontrolled division of cells in the CML. Nilotinib disrupts the signaling route of the protein kinase enzyme which targets the BCR-ABL protein and inhibits the growth and spread of cancer cells. 

Uses of undefined

This medicine is used to treat a type of leukemia called  Philadelphia chromosome-positive chronic myeloid leukemia (Ph-positive CML), a blood cancer with abnormal production of WBC. In adult and pediatric patients, it is used in a patient who is newly diagnosed with Chronic Myeloid Leukemia (CML) and those facing side effects from previous treatment. Additionally, it is also used in patients with no longer respond to the previous treatment including Imatinib.

undefined Drug administaration and Dosage available

Take Nilotinib as advised by your physician. Swallow the medicine with a glass of water. Do not crush, chew, or open the medicine. Your doctor will decide the correct dose and duration for you based on your age, body weight, and disease condition. Do not stop taking Nilotinib unless your doctor advises you to stop.

Warnings, Precautions and Side Effects of undefined


Notify your doctor if you have or had a history of heart conditions (heart attack, abnormal electric signal), chest pain, brain stroke, or claudication ( condition of blood flow in the leg). Inform your doctor if you have liver or pancreas disorder, or suffering from a lack of potassium or magnesium. You need to tell your doctor about all the medications especially if you take medicine to lower your blood cholesterol. Tell your doctor about your underlying condition especially inform about if you have or ever had a hepatitis B infection; this medicine can activate HPV again which can be fatal in some cases.


Do not take this medicine if you are allergic to Nilotinib or the other ingredients of this medicine. During the treatment, your doctor may conduct a regular blood test to monitor the liver and pancreas function, and the number of blood cells (WBC, RBC, platelets). Also to monitor the heart condition (prolongation of the QT interval), electrolytes in the body, and the level of sugar and fats. Before starting the treatment, inform your doctor if you are pregnant or think you may be pregnant or are planning to have a baby because your physician shall prescribe Aprepitant only if it is essential. Use effective contraception. Consult your doctor for more information. 

Side Effects

The most common side effects of Aprepitant are nausea, vomiting, diarrhea, headache, muscle pain, stomach pain, hair loss, tiredness, constipation, slowing of growth in children, loss of appetite, sleeplessness, depression, anxiety, and musculoskeletal pain.

Serious side effects while taking Aprepitant are sudden weight gain, swelling in hands, feet, ankles, or face chest pain. blood pressure (high and low), discoloration of the tongue, lips, or skin (blue), abnormal heart (irregular heartbeat), hair loss, vision problems, stomach pain, vomiting of blood, and blood in stools. yellowing of the skin, eyes, and dark urine, high blood sugar levels, and sensitivity to light.

Word Of Advice

Store at room temperature below 30°C to 25°C. Keep out of sight and reach of children. Store in the original package in order to protect it from moisture. Contact your doctor for more concerns. Do not double the dose if missed the turn. Contact your doctor immediately if you double dose. Based on your condition your doctor may prescribe a lower dose. Nilotinib can be used by people aged 65 years and over with the same dose as other adults. Tell your doctor if you experience any irregular heartbeats or any signs of a heart condition because this can lead to serious complications like sudden death. 

Frequently Asked Question


  1. Robert J. Thomson; Majid Moshirfar; Yasmyne Ronquillo; Tyrosine Kinase Inhibitors, [Revised on 21st Jan 2021]; [Accessed on 22st April 2023];
  2. Novartis Pharmaceuticals UK Ltd, Electronic Medicines Compendium (EMC), [Revised on May 2022], [Accessed on 21st April 2023],
  3. Novartis, US Food & Drug Administration, [Revised on Sep 2021], [Accessed on 21st April 2023],


The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.